238 related articles for article (PubMed ID: 17408938)
1. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
2. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
3. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
4. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
5. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
[TBL] [Abstract][Full Text] [Related]
6. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
7. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
[TBL] [Abstract][Full Text] [Related]
8. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential.
LeCureux L; Cheng CS; Herbst J; Reilly TP; Lehman-McKeeman L; Otieno M
Toxicol In Vitro; 2011 Dec; 25(8):1934-43. PubMed ID: 21767630
[TBL] [Abstract][Full Text] [Related]
10. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE.
Bhandari N; Figueroa DJ; Lawrence JW; Gerhold DL
Assay Drug Dev Technol; 2008 Jun; 6(3):407-19. PubMed ID: 18537465
[TBL] [Abstract][Full Text] [Related]
11. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis.
Fujimura H; Murakami N; Kurabe M; Toriumi W
J Appl Toxicol; 2009 May; 29(4):356-63. PubMed ID: 19224547
[TBL] [Abstract][Full Text] [Related]
12. A strategy for risk management of drug-induced phospholipidosis.
Chatman LA; Morton D; Johnson TO; Anway SD
Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
[TBL] [Abstract][Full Text] [Related]
13. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis.
Kuroda Y; Saito M
Toxicol In Vitro; 2010 Mar; 24(2):661-8. PubMed ID: 19786086
[TBL] [Abstract][Full Text] [Related]
14. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers to monitor drug-induced phospholipidosis.
Baronas ET; Lee JW; Alden C; Hsieh FY
Toxicol Appl Pharmacol; 2007 Jan; 218(1):72-8. PubMed ID: 17156806
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
Almela MJ; Torres PA; Lozano S; Herreros E
Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA
Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356
[TBL] [Abstract][Full Text] [Related]
18. X-ray microanalysis of cultured alveolar macrophages with phospholipidosis.
Lee P; Kirk RG; Reasor MJ
Exp Mol Pathol; 1993 Apr; 58(2):96-104. PubMed ID: 8388333
[TBL] [Abstract][Full Text] [Related]
19. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery.
Zhou L; Geraci G; Hess S; Yang L; Wang J; Argikar U
Anal Chem; 2011 Sep; 83(18):6980-7. PubMed ID: 21790130
[TBL] [Abstract][Full Text] [Related]
20. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]